Each accepted BIO-X project receives up to 2 MSEK over two years to cover approximately 50% of the estimated budget. Your research group and/or project partners cover the remaining costs, either in cash or in kind.
Hand-picked senior experts
Throughout the project, you receive support and guidance from an experienced BIO-X coach plus an advisory board consisting of senior experts hand-picked from industry, academia and healthcare.
Additional expertise, in areas such as product development, market knowledge or regulatory issues, is brought in and tailored to your requirements from well-established BIO-X networks. You will:
- Increase your chance of success
- Get support from an experienced BIO-X coach plus industry and clinical partners
- Strengthen your entrepreneurial and commercial skills, broaden your network
- See your idea become a potential value-adding life science product
Development of plans and stop/go checkpoints
Verifying the long-term technical and commercial viability of your idea begins with developing a well-defined industrial-like project plan. This includes research and business planning, market assessments and critical stop/go checkpoints. It culminates in an attractive investment opportunity for national or international investors and companies.
Coaching and expert support throughout the process
A dedicated BIO-X coach with access to our extensive network supports you throughout the project process. This network can be called upon whenever advice on specific topics such as quality control or regulatory issues is needed. It is also an invaluable source of potential project partners from industry, academia or healthcare.
Numbers that count for success
Out of ten completed BIO-X projects, seven have continued in different companies.
From 2010 to 2015, 254 project proposals were received. Eighty-nine were selected to work together with a BIO-X coach to expand their initial proposal into a more detailed project plan, and to establish a network of relevant experts from the life science industry. Twenty-eight of the 89 then received BIO-X financial funding and tailored expert support.
BIO-X 2013: New opportunities for existing drugs. Recipients Peetra Magnusson, Sara Mangsbo, Mats J. Olsson and Cecilia Söderberg-Naucler.